Latest Antibody Stories

ROCKVILLE, Md., July 19, 2012 /PRNewswire/ -- OriGene Technologies, Inc. and Canada's Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) today announced the selection of OriGene Technologies as a major collaboration and development partner to implement blood-based protein assays in heart and kidney transplantation. This multi-year, collaborative project funded by multiple partners will provide monitoring and predictive blood tests, based upon OriGene's extensive...

CARLSBAD, Calif., July 19, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced it has signed a collaborative partnership with the Structural Genomics Consortium (SGC), and several groups of leading expert scientists in antibody technology at the Universities of Chicago and Toronto, to generate a first-ever master set of quality epigenetic recombinant antibodies for use in disease-related research. The first 58 of 200 highly-specific antibodies to be...

CARLSBAD, Calif., July 11, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ:LIFE - News) today announced that it will accelerate development of its Ion Torrent Semiconductor technology for a broad set of proteomic and antibody-based applications after passing internal Life Technologies R&D milestones. Proteomic and antibody-based technologies are used prevalently across multiple addressable markets in research, applied sciences and clinical diagnostics. Research and...

WHEATON Industries has acquired the CELLine Bioreactor Flask Line for Antibody and Protein Production from Wilson Wolf Manufacturing Corporation Millville, NJ (PRWEB) July 09, 2012 WHEATON has acquired the CELLine dual membrane, cell culture flasks from Wilson Wolf Manufacturing Corporation. WHEATON has also entered into a long term strategic partnership with Wilson Wolf Manufacturing Corporation for further product development in high density cell culture devices for the production of...

Researchers probe origin of optimized antibodies against infections An organism's ability to make new antibodies and use them to optimize its own immune defenses is of central importance in the fight against pathogens. In the case of severe infections, the overall relative speed with which an immune response proceeds could mean the difference between life and death. An international team of scientists, among them systems immunologist Prof. Michael Meyer-Hermann of the Helmholtz Centre for...

ROTTERDAM, Netherlands, June 27, 2012 /PRNewswire/ -- Data presented today from the Privigen Impact on Mobility and Autonomy (PRIMA) trial at the Peripheral Nerve Society Inflammatory Neuropathy Consortium Meeting in Rotterdam, Netherlands, suggests that treatment with Privigen® [Immune Globulin Intravenous (Human), 10% Liquid], an intravenous immunoglobulin (IVIg), may lead to improvement in function in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). PRIMA,...

NORCROSS, Ga., June 18, 2012 /PRNewswire/ -- RayBiotech, Inc. and the combined genotyping core facility for Oslo University Hospital and the University of Oslo, located at the Institute for Cancer Research, announced the execution of an agreement to collaborate for the implementation of antibody-based sample analysis services. Under the terms of the agreement, the combined core facility will provide a comprehensive service utilizing RayBiotech's proprietary antibody arrays for the...

PRINCETON, N.J., BASEL, Switzerland and SOUTH SAN FRANCISCO, Calif., June 13, 2012 /PRNewswire/ -- Five Prime Therapeutics, Inc. ("FivePrime") has entered into research and commercial agreements with BioWa, Inc. and Lonza to use their POTELLIGENT® CHOK1SV Cell Line for the research, development and production of multiple proprietary antibodies in FivePrime's oncology pipeline. POTELLIGENT® CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the...

TSX Venture: QPT EDMONTON, June 5, 2012 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announces the signing of an $8,000,000 investment agreement to primarily support the Company's clinical trial programs. Quest has signed an investment agreement with parties from South Korea to provide up to $8,000,000 over the next 12 months to fund the...

FARMINGTON, Conn., June 5, 2012 /PRNewswire-iReach/ -- Global Information Inc. is pleased to announce limited available early bird discounted registration for three important international healthcare and biotechnology conferences: PEGS Europe - Protein & Antibody Engineering Summit 2012 November 6 - 8, 2012 - Vienna, Austria - The Fourth Annual Protein & Antibody Engineering Summit (PEGS Europe) presents an exciting opportunity to hear from leaders in the fields of novel...